InVitro International
IVRO · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.32 | 0.04 | -0.60 | 0.42 |
| FCF Yield | -0.17% | 1.23% | -0.96% | -0.28% |
| EV / EBITDA | 34.17 | 29.02 | 109.51 | 55.48 |
| Quality | ||||
| ROIC | 0.90% | 1.91% | 0.35% | 1.25% |
| Gross Margin | 81.82% | 81.86% | 81.10% | 81.93% |
| Cash Conversion Ratio | -0.03 | 0.39 | -1.22 | -0.17 |
| Growth | ||||
| Revenue 3-Year CAGR | 3.51% | 4.75% | 0.47% | -1.36% |
| Free Cash Flow Growth | -112.44% | 196.33% | -227.75% | 48.42% |
| Safety | ||||
| Net Debt / EBITDA | -13.36 | -1.71 | -3.42 | -2.08 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.20 | 0.22 | 0.19 | 0.25 |
| Cash Conversion Cycle | 461.55 | 423.55 | 475.10 | 390.17 |